KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) CEO Sells $89,620.88 in Stock

KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) CEO Benjamin L. Palleiko sold 7,352 shares of KalVista Pharmaceuticals stock in a transaction dated Monday, September 9th. The shares were sold at an average price of $12.19, for a total value of $89,620.88. Following the completion of the transaction, the chief executive officer now owns 250,800 shares of the company’s stock, valued at approximately $3,057,252. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link.

KalVista Pharmaceuticals Trading Down 5.6 %

Shares of NASDAQ KALV traded down $0.66 during mid-day trading on Tuesday, reaching $11.21. The company had a trading volume of 556,002 shares, compared to its average volume of 501,665. The firm has a 50 day simple moving average of $13.16 and a two-hundred day simple moving average of $12.39. KalVista Pharmaceuticals, Inc. has a 52-week low of $7.21 and a 52-week high of $16.88. The stock has a market cap of $484.50 million, a P/E ratio of -3.30 and a beta of 0.89.

KalVista Pharmaceuticals (NASDAQ:KALV) last issued its quarterly earnings data on Thursday, September 5th. The specialty pharmaceutical company reported ($0.87) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.91) by $0.04. On average, equities analysts expect that KalVista Pharmaceuticals, Inc. will post -3.57 EPS for the current year.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in KALV. Price T Rowe Associates Inc. MD boosted its holdings in shares of KalVista Pharmaceuticals by 4.5% in the first quarter. Price T Rowe Associates Inc. MD now owns 22,142 shares of the specialty pharmaceutical company’s stock valued at $263,000 after acquiring an additional 944 shares during the period. ClariVest Asset Management LLC boosted its stake in KalVista Pharmaceuticals by 2.8% during the 2nd quarter. ClariVest Asset Management LLC now owns 57,096 shares of the specialty pharmaceutical company’s stock worth $673,000 after purchasing an additional 1,535 shares during the period. Nicholas Investment Partners LP grew its position in KalVista Pharmaceuticals by 0.9% during the 2nd quarter. Nicholas Investment Partners LP now owns 184,358 shares of the specialty pharmaceutical company’s stock worth $2,172,000 after purchasing an additional 1,714 shares during the last quarter. nVerses Capital LLC acquired a new position in KalVista Pharmaceuticals in the second quarter valued at $25,000. Finally, The Manufacturers Life Insurance Company raised its stake in KalVista Pharmaceuticals by 27.3% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 15,437 shares of the specialty pharmaceutical company’s stock valued at $182,000 after acquiring an additional 3,314 shares during the last quarter.

Analyst Ratings Changes

A number of research firms have weighed in on KALV. Cantor Fitzgerald reissued an “overweight” rating on shares of KalVista Pharmaceuticals in a research note on Monday. Needham & Company LLC reissued a “buy” rating and issued a $32.00 target price on shares of KalVista Pharmaceuticals in a research report on Friday. Finally, HC Wainwright reiterated a “buy” rating and issued a $20.00 target price on shares of KalVista Pharmaceuticals in a report on Friday.

About KalVista Pharmaceuticals

KalVista Pharmaceuticals, Inc, a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of small molecule protease inhibitors for diseases with unmet needs in the United States. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME); and oral plasma kallikrein inhibitors.